BIRMINGHAM, Ala., Sept. 19, 2025 /PRNewswire/ -- Acclinate, the health equity company pioneering community-powered engagement and inclusive clinical trial enrollment,...
Elevating Performance and Efficiency for Clinical and Public Health Labs WILMINGTON, Del., Sept. 19, 2025 /PRNewswire/ -- LabWare, Inc., the...
Annual event recognizes top digital health solutions and connects international thought leaders OLATHE, Kan., Sept. 19, 2025 /PRNewswire/ -- Garmin...
WILMINGTON, Del., Sept. 19, 2025 /PRNewswire/ -- Brand Engagement Network, Inc. (Nasdaq: BNAI) ("BEN"), an innovator in human-like AI Agents...
MESA, ARIZONA / ACCESS Newswire / September 19, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), a pioneer in AI-powered...
Pending the European Commission’s final decision, nipocalimab could be the first FcRn blocker approved in both adult and adolescent gMG...
Lunsumio provides high and long-lasting response rates, with approximately two-thirds of patients with a complete response in remission after four...
OVATION 3 pivotal Phase 3 trial is currently advancing IMNN-001, with several patients being treated LAWRENCEVILLE, N.J., Sept. 19, 2025...
neffy 1 mg and 2 mg doses approved by Japanese regulators neffy offers a new delivery method for epinephrine in...
DALLAS, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence...
– Approval triggers $10 million cash milestone payment to Verrica – – YCANTH® approval in Japan addresses significant unmet need...
Bylvay® is the first once-daily ileal bile acid transport inhibitor to be approved as a treatment for pruritus associated with...
Pending the European Commission’s final decision, nipocalimab could be the first FcRn blocker approved in both adult and adolescent gMG...
Inmazeb® (atoltivimab, maftivimab, and odesivimab-ebgn) was the first treatment approved by the U.S. Food and Drug Administration (FDA) for Orthoebolavirus zairense,...
SAN JUAN CAPISTRANO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group...
Idorsia receives approval from Swissmedic for JERAYGO™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment...
CUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...
TOKYO, Sept. 18, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) today announced that its subsidiary, MEDIROM...
New York, NY, Sept. 18, 2025 (GLOBE NEWSWIRE) -- The soft launch of iCare ABA Therapy is drawing attention across...
NEW YORK, Sept. 19, 2025 /PRNewswire/ -- Truelli, a pioneering healthtech startup, is advancing its research and development on the...